ANNA WARFIELD, M.D., Ph.D.; DAVID M. FINKEL, M.D.; NORMAN J. SCHATZ, M.D.; PETER J. SAVINO, M.D.; PETER J. SNYDER, M.D.
Six men with prolactin-secreting pituitary macroadenomas and deficiencies of pituitary hormones other than gonadotrophins were treated with bromocriptine for 6 months. During treatment the serum prolactin concentration decreased markedly in all six patients, and in four adenoma size decreased and visual function improved. Two patients who were hypothyroid before bromocriptine treatment were euthyroid during the sixth month of treatment, and the one patient who was hypoadrenal before treatment was euadrenal during treatment. Two of the six men who had subnormal growth hormone secretion before treatment had normal growth hormone secretion during treatment. We conclude that pituitary hormonal functions may improve during bromocriptine treatment for prolactin-secreting pituitary macroadenomas. This improvement may result from decompression of other pituitary cells, because correction of hypothyroidism by bromocriptine was accompanied by conversion from an absent to a normal thyrotrophin response to thyrotrophin-releasing hormone.
Learn more about subscription options.
Register Now for a free account.
WARFIELD A, FINKEL DM, SCHATZ NJ, SAVINO PJ, SNYDER PJ. Bromocriptine Treatment of Prolactin-Secreting Pituitary Adenomas May Restore Pituitary Function. Ann Intern Med. 1984;101:783–785. doi: 10.7326/0003-4819-101-6-783
Download citation file:
Published: Ann Intern Med. 1984;101(6):783-785.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only